Teva Pharmaceutical Industries Ltd.

TEVA ·Healthcare, Drug Manufacturers - General

← 5Y 10Y MAX →

Cash Flow History

Operating Cash Flow Free Cash Flow CapEx Share-Based Compensation

Period	Operating Cash Flow	Free Cash Flow	CapEx	Share-Based Compensation
Mar 2017	$136.0M	$-66.0M	$202.0M	$40.0M
Jun 2017	$435.0M	$242.0M	$193.0M	$35.0M
Sep 2017	$795.0M	$583.0M	$212.0M	$31.0M
Dec 2017	$859.0M	$592.0M	$267.0M	$27.0M
Mar 2018	$1.50B	$1.33B	$163.0M	$30.0M
Jun 2018	$162.0M	$26.0M	$136.0M	$47.0M
Sep 2018	$421.0M	$282.0M	$139.0M	$45.0M
Dec 2018	$367.0M	$154.0M	$213.0M	$33.0M
Mar 2019	$112.0M	$-13.0M	$125.0M	$34.0M
Jun 2019	$-227.0M	$-339.0M	$112.0M	$30.0M
Sep 2019	$325.0M	$156.0M	$169.0M	$35.0M
Dec 2019	$538.0M	$419.0M	$119.0M	$20.0M
Mar 2020	$305.0M	$177.0M	$128.0M	$30.0M
Jun 2020	$273.0M	$142.0M	$131.0M	$32.0M
Sep 2020	$307.0M	$164.0M	$143.0M	$29.0M
Dec 2020	$331.0M	$155.0M	$176.0M	$38.0M
Mar 2021	$-405.0M	$-555.0M	$150.0M	$31.0M
Jun 2021	$218.0M	$105.0M	$113.0M	$29.0M
Sep 2021	$529.0M	$383.0M	$146.0M	$26.0M
Dec 2021	$456.0M	$303.0M	$153.0M	$33.0M
Mar 2022	$-49.0M	$-206.0M	$157.0M	$24.0M
Jun 2022	$123.0M	$-4.0M	$127.0M	$39.0M
Sep 2022	$543.0M	$421.0M	$122.0M	$26.0M
Dec 2022	$973.0M	$831.0M	$142.0M	$35.0M
Mar 2023	$-145.0M	$-284.0M	$139.0M	$32.0M
Jun 2023	$324.0M	$205.0M	$119.0M	$30.0M
Sep 2023	$5.0M	$-144.0M	$149.0M	$31.0M
Dec 2023	$1.18B	$1.07B	$119.0M	$28.0M
Mar 2024	$-124.0M	$-248.0M	$124.0M	$28.0M
Jun 2024	$103.0M	$6.0M	$97.0M	$32.0M
Sep 2024	$693.0M	$545.0M	$148.0M	$29.0M
Dec 2024	$575.0M	$446.0M	$129.0M	$34.0M
Mar 2025	$-105.0M	$-232.0M	$127.0M	$34.0M
Jun 2025	$227.0M	$131.0M	$96.0M	$38.0M
Sep 2025	$369.0M	$233.0M	$136.0M	$34.0M
Dec 2025	$1.16B	$1.02B	$142.0M	$51.0M
Mar 2026	$-40.0M	$-208.0M	$168.0M	$43.0M
Jun 2026	$411.0M	$307.0M	$104.0M	$40.0M